家族性アミロイド多発神経障害（FAP）の世界市場（～2026年）

• 英文タイトル：Global Familial Amyloid Polyneuropathy Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY11920
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、91ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は家族性アミロイド多発神経障害（FAP）のグローバル市場について調査・分析したレポートです。種類別（FAP-I、FAP-II、FAP-III、FAP-IV）市場規模、用途別（病院・クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別家族性アミロイド多発神経障害（FAP）の競争状況、市場シェア
・世界の家族性アミロイド多発神経障害（FAP）市場：種類別市場規模 2015年-2020年（FAP-I、FAP-II、FAP-III、FAP-IV）
・世界の家族性アミロイド多発神経障害（FAP）市場：種類別市場規模予測 2021年-2026年（FAP-I、FAP-II、FAP-III、FAP-IV）
・世界の家族性アミロイド多発神経障害（FAP）市場：用途別市場規模 2015年-2020年（病院・クリニック、その他）
・世界の家族性アミロイド多発神経障害（FAP）市場：用途別市場規模予測 2021年-2026年（病院・クリニック、その他）
・北米の家族性アミロイド多発神経障害（FAP）市場分析：米国、カナダ
・ヨーロッパの家族性アミロイド多発神経障害（FAP）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの家族性アミロイド多発神経障害（FAP）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の家族性アミロイド多発神経障害（FAP）市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの家族性アミロイド多発神経障害（FAP）市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Pfizer、GSK、Ionis、Alnylam、Corino Therapeutics、Proclara Bioscience、Arcturus Therapeutics
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle.
Globally, development of new drugs for treatment of familial amyloid polyneuropathy, and rise in the prevalence of familial amyloid polyneuropathy are the prime growth drivers of familial amyloid polyneuropathy market.

Market Analysis and Insights: Global Familial Amyloid Polyneuropathy Market
The global Familial Amyloid Polyneuropathy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Familial Amyloid Polyneuropathy Scope and Market Size
Familial Amyloid Polyneuropathy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Familial Amyloid Polyneuropathy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Pfizer
GSK
Ionis
Alnylam
Corino Therapeutics
Proclara Bioscience
Arcturus Therapeutics
…

Market segment by Type, the product can be split into
FAP-I
FAP-II
FAP-III
FAP-IV
Market segment by Application, split into
Hospitals and Clinics
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Familial Amyloid Polyneuropathy Revenue
1.4 Market by Type
1.4.1 Global Familial Amyloid Polyneuropathy Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 FAP-I
1.4.3 FAP-II
1.4.4 FAP-III
1.4.5 FAP-IV
1.5 Market by Application
1.5.1 Global Familial Amyloid Polyneuropathy Market Share by Application: 2020 VS 2026
1.5.2 Hospitals and Clinics
1.5.3 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Familial Amyloid Polyneuropathy Market Perspective (2015-2026)
2.2 Global Familial Amyloid Polyneuropathy Growth Trends by Regions
2.2.1 Familial Amyloid Polyneuropathy Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Familial Amyloid Polyneuropathy Historic Market Share by Regions (2015-2020)
2.2.3 Familial Amyloid Polyneuropathy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Familial Amyloid Polyneuropathy Market Growth Strategy
2.3.6 Primary Interviews with Key Familial Amyloid Polyneuropathy Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Familial Amyloid Polyneuropathy Players by Market Size
3.1.1 Global Top Familial Amyloid Polyneuropathy Players by Revenue (2015-2020)
3.1.2 Global Familial Amyloid Polyneuropathy Revenue Market Share by Players (2015-2020)
3.1.3 Global Familial Amyloid Polyneuropathy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Familial Amyloid Polyneuropathy Market Concentration Ratio
3.2.1 Global Familial Amyloid Polyneuropathy Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Familial Amyloid Polyneuropathy Revenue in 2019
3.3 Familial Amyloid Polyneuropathy Key Players Head office and Area Served
3.4 Key Players Familial Amyloid Polyneuropathy Product Solution and Service
3.5 Date of Enter into Familial Amyloid Polyneuropathy Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Familial Amyloid Polyneuropathy Historic Market Size by Type (2015-2020)
4.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Familial Amyloid Polyneuropathy Market Size by Application (2015-2020)
5.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Familial Amyloid Polyneuropathy Market Size (2015-2020)
6.2 Familial Amyloid Polyneuropathy Key Players in North America (2019-2020)
6.3 North America Familial Amyloid Polyneuropathy Market Size by Type (2015-2020)
6.4 North America Familial Amyloid Polyneuropathy Market Size by Application (2015-2020)

7 Europe
7.1 Europe Familial Amyloid Polyneuropathy Market Size (2015-2020)
7.2 Familial Amyloid Polyneuropathy Key Players in Europe (2019-2020)
7.3 Europe Familial Amyloid Polyneuropathy Market Size by Type (2015-2020)
7.4 Europe Familial Amyloid Polyneuropathy Market Size by Application (2015-2020)

8 China
8.1 China Familial Amyloid Polyneuropathy Market Size (2015-2020)
8.2 Familial Amyloid Polyneuropathy Key Players in China (2019-2020)
8.3 China Familial Amyloid Polyneuropathy Market Size by Type (2015-2020)
8.4 China Familial Amyloid Polyneuropathy Market Size by Application (2015-2020)

9 Japan
9.1 Japan Familial Amyloid Polyneuropathy Market Size (2015-2020)
9.2 Familial Amyloid Polyneuropathy Key Players in Japan (2019-2020)
9.3 Japan Familial Amyloid Polyneuropathy Market Size by Type (2015-2020)
9.4 Japan Familial Amyloid Polyneuropathy Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Familial Amyloid Polyneuropathy Market Size (2015-2020)
10.2 Familial Amyloid Polyneuropathy Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Familial Amyloid Polyneuropathy Market Size by Type (2015-2020)
10.4 Southeast Asia Familial Amyloid Polyneuropathy Market Size by Application (2015-2020)

11 India
11.1 India Familial Amyloid Polyneuropathy Market Size (2015-2020)
11.2 Familial Amyloid Polyneuropathy Key Players in India (2019-2020)
11.3 India Familial Amyloid Polyneuropathy Market Size by Type (2015-2020)
11.4 India Familial Amyloid Polyneuropathy Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Familial Amyloid Polyneuropathy Market Size (2015-2020)
12.2 Familial Amyloid Polyneuropathy Key Players in Central & South America (2019-2020)
12.3 Central & South America Familial Amyloid Polyneuropathy Market Size by Type (2015-2020)
12.4 Central & South America Familial Amyloid Polyneuropathy Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Familial Amyloid Polyneuropathy Introduction
13.1.4 Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 GSK
13.2.1 GSK Company Details
13.2.2 GSK Business Overview
13.2.3 GSK Familial Amyloid Polyneuropathy Introduction
13.2.4 GSK Revenue in Familial Amyloid Polyneuropathy Business (2015-2020)
13.2.5 GSK Recent Development
13.3 Ionis
13.3.1 Ionis Company Details
13.3.2 Ionis Business Overview
13.3.3 Ionis Familial Amyloid Polyneuropathy Introduction
13.3.4 Ionis Revenue in Familial Amyloid Polyneuropathy Business (2015-2020)
13.3.5 Ionis Recent Development
13.4 Alnylam
13.4.1 Alnylam Company Details
13.4.2 Alnylam Business Overview
13.4.3 Alnylam Familial Amyloid Polyneuropathy Introduction
13.4.4 Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2015-2020)
13.4.5 Alnylam Recent Development
13.5 Corino Therapeutics
13.5.1 Corino Therapeutics Company Details
13.5.2 Corino Therapeutics Business Overview
13.5.3 Corino Therapeutics Familial Amyloid Polyneuropathy Introduction
13.5.4 Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2015-2020)
13.5.5 Corino Therapeutics Recent Development
13.6 Proclara Bioscience
13.6.1 Proclara Bioscience Company Details
13.6.2 Proclara Bioscience Business Overview
13.6.3 Proclara Bioscience Familial Amyloid Polyneuropathy Introduction
13.6.4 Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2015-2020)
13.6.5 Proclara Bioscience Recent Development
13.7 Arcturus Therapeutics
13.7.1 Arcturus Therapeutics Company Details
13.7.2 Arcturus Therapeutics Business Overview
13.7.3 Arcturus Therapeutics Familial Amyloid Polyneuropathy Introduction
13.7.4 Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2015-2020)
13.7.5 Arcturus Therapeutics Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Familial Amyloid Polyneuropathy Key Market Segments
Table 2. Key Players Covered: Ranking by Familial Amyloid Polyneuropathy Revenue
Table 3. Ranking of Global Top Familial Amyloid Polyneuropathy Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Familial Amyloid Polyneuropathy Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of FAP-I
Table 6. Key Players of FAP-II
Table 7. Key Players of FAP-III
Table 8. Key Players of FAP-IV
Table 9. Global Familial Amyloid Polyneuropathy Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Familial Amyloid Polyneuropathy Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Familial Amyloid Polyneuropathy Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Familial Amyloid Polyneuropathy Market Share by Regions (2015-2020)
Table 13. Global Familial Amyloid Polyneuropathy Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Familial Amyloid Polyneuropathy Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Familial Amyloid Polyneuropathy Market Growth Strategy
Table 19. Main Points Interviewed from Key Familial Amyloid Polyneuropathy Players
Table 20. Global Familial Amyloid Polyneuropathy Revenue by Players (2015-2020) (Million US$)
Table 21. Global Familial Amyloid Polyneuropathy Market Share by Players (2015-2020)
Table 22. Global Top Familial Amyloid Polyneuropathy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Familial Amyloid Polyneuropathy as of 2019)
Table 23. Global Familial Amyloid Polyneuropathy by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Familial Amyloid Polyneuropathy Product Solution and Service
Table 26. Date of Enter into Familial Amyloid Polyneuropathy Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Familial Amyloid Polyneuropathy Market Size by Type (2015-2020) (Million US$)
Table 29. Global Familial Amyloid Polyneuropathy Market Size Share by Type (2015-2020)
Table 30. Global Familial Amyloid Polyneuropathy Revenue Market Share by Type (2021-2026)
Table 31. Global Familial Amyloid Polyneuropathy Market Size Share by Application (2015-2020)
Table 32. Global Familial Amyloid Polyneuropathy Market Size by Application (2015-2020) (Million US$)
Table 33. Global Familial Amyloid Polyneuropathy Market Size Share by Application (2021-2026)
Table 34. North America Key Players Familial Amyloid Polyneuropathy Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Familial Amyloid Polyneuropathy Market Share (2019-2020)
Table 36. North America Familial Amyloid Polyneuropathy Market Size by Type (2015-2020) (Million US$)
Table 37. North America Familial Amyloid Polyneuropathy Market Share by Type (2015-2020)
Table 38. North America Familial Amyloid Polyneuropathy Market Size by Application (2015-2020) (Million US$)
Table 39. North America Familial Amyloid Polyneuropathy Market Share by Application (2015-2020)
Table 40. Europe Key Players Familial Amyloid Polyneuropathy Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Familial Amyloid Polyneuropathy Market Share (2019-2020)
Table 42. Europe Familial Amyloid Polyneuropathy Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Familial Amyloid Polyneuropathy Market Share by Type (2015-2020)
Table 44. Europe Familial Amyloid Polyneuropathy Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Familial Amyloid Polyneuropathy Market Share by Application (2015-2020)
Table 46. China Key Players Familial Amyloid Polyneuropathy Revenue (2019-2020) (Million US$)
Table 47. China Key Players Familial Amyloid Polyneuropathy Market Share (2019-2020)
Table 48. China Familial Amyloid Polyneuropathy Market Size by Type (2015-2020) (Million US$)
Table 49. China Familial Amyloid Polyneuropathy Market Share by Type (2015-2020)
Table 50. China Familial Amyloid Polyneuropathy Market Size by Application (2015-2020) (Million US$)
Table 51. China Familial Amyloid Polyneuropathy Market Share by Application (2015-2020)
Table 52. Japan Key Players Familial Amyloid Polyneuropathy Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Familial Amyloid Polyneuropathy Market Share (2019-2020)
Table 54. Japan Familial Amyloid Polyneuropathy Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Familial Amyloid Polyneuropathy Market Share by Type (2015-2020)
Table 56. Japan Familial Amyloid Polyneuropathy Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Familial Amyloid Polyneuropathy Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Familial Amyloid Polyneuropathy Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Familial Amyloid Polyneuropathy Market Share (2019-2020)
Table 60. Southeast Asia Familial Amyloid Polyneuropathy Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Familial Amyloid Polyneuropathy Market Share by Type (2015-2020)
Table 62. Southeast Asia Familial Amyloid Polyneuropathy Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Familial Amyloid Polyneuropathy Market Share by Application (2015-2020)
Table 64. India Key Players Familial Amyloid Polyneuropathy Revenue (2019-2020) (Million US$)
Table 65. India Key Players Familial Amyloid Polyneuropathy Market Share (2019-2020)
Table 66. India Familial Amyloid Polyneuropathy Market Size by Type (2015-2020) (Million US$)
Table 67. India Familial Amyloid Polyneuropathy Market Share by Type (2015-2020)
Table 68. India Familial Amyloid Polyneuropathy Market Size by Application (2015-2020) (Million US$)
Table 69. India Familial Amyloid Polyneuropathy Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Familial Amyloid Polyneuropathy Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Familial Amyloid Polyneuropathy Market Share (2019-2020)
Table 72. Central & South America Familial Amyloid Polyneuropathy Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Familial Amyloid Polyneuropathy Market Share by Type (2015-2020)
Table 74. Central & South America Familial Amyloid Polyneuropathy Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Familial Amyloid Polyneuropathy Market Share by Application (2015-2020)
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Product
Table 79. Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2015-2020) (Million US$)
Table 80. Pfizer Recent Development
Table 81. GSK Company Details
Table 82. GSK Business Overview
Table 83. GSK Product
Table 84. GSK Revenue in Familial Amyloid Polyneuropathy Business (2015-2020) (Million US$)
Table 85. GSK Recent Development
Table 86. Ionis Company Details
Table 87. Ionis Business Overview
Table 88. Ionis Product
Table 89. Ionis Revenue in Familial Amyloid Polyneuropathy Business (2015-2020) (Million US$)
Table 90. Ionis Recent Development
Table 91. Alnylam Company Details
Table 92. Alnylam Business Overview
Table 93. Alnylam Product
Table 94. Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2015-2020) (Million US$)
Table 95. Alnylam Recent Development
Table 96. Corino Therapeutics Company Details
Table 97. Corino Therapeutics Business Overview
Table 98. Corino Therapeutics Product
Table 99. Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2015-2020) (Million US$)
Table 100. Corino Therapeutics Recent Development
Table 101. Proclara Bioscience Company Details
Table 102. Proclara Bioscience Business Overview
Table 103. Proclara Bioscience Product
Table 104. Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2015-2020) (Million US$)
Table 105. Proclara Bioscience Recent Development
Table 106. Arcturus Therapeutics Company Details
Table 107. Arcturus Therapeutics Business Overview
Table 108. Arcturus Therapeutics Product
Table 109. Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2015-2020) (Million US$)
Table 110. Arcturus Therapeutics Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Familial Amyloid Polyneuropathy Market Share by Type: 2020 VS 2026
Figure 2. FAP-I Features
Figure 3. FAP-II Features
Figure 4. FAP-III Features
Figure 5. FAP-IV Features
Figure 6. Global Familial Amyloid Polyneuropathy Market Share by Application: 2020 VS 2026
Figure 7. Hospitals and Clinics Case Studies
Figure 8. Others Case Studies
Figure 9. Familial Amyloid Polyneuropathy Report Years Considered
Figure 10. Global Familial Amyloid Polyneuropathy Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Familial Amyloid Polyneuropathy Market Share by Regions: 2020 VS 2026
Figure 12. Global Familial Amyloid Polyneuropathy Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Familial Amyloid Polyneuropathy Market Share by Players in 2019
Figure 15. Global Top Familial Amyloid Polyneuropathy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Familial Amyloid Polyneuropathy as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Familial Amyloid Polyneuropathy Revenue in 2019
Figure 17. North America Familial Amyloid Polyneuropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Familial Amyloid Polyneuropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Familial Amyloid Polyneuropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Familial Amyloid Polyneuropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Familial Amyloid Polyneuropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Familial Amyloid Polyneuropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Familial Amyloid Polyneuropathy Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed

以下、関連資料のご紹介

ヘテロ接合性家族性高コレステロール血症薬の世界市場（～2026年）

Global Heterozygous Familial Hypercholesterolemia Drug Market Insights and Forecast to 2026
MRC2-11QY01147 2020年11月20日 112Pages
当調査資料はヘテロ接合性家族性高コレステロール血症薬のグローバル市場について調査・分析したレポートです。種類別（ジェムカベンカルシウム、MGL-3196、ST-103、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イ...

ホモ接合性家族性高コレステロール血症治療の世界市場（～2026年）

Global Homozygous Familial Hypercholesterolemia Treatment Market Insights and Forecast to 2026
MRC2-11QY01350 2020年11月20日 110Pages
当調査資料はホモ接合性家族性高コレステロール血症治療のグローバル市場について調査・分析したレポートです。種類別（AEM-2802、AEM-2814、アリロクマブ、エビナクマブ、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギ...

膵島アミロイドポリペプチドの世界市場（～2026年）

Global Islet Amyloid Polypeptide Market Insights and Forecast to 2026
MRC2-11QY01834 2020年11月20日 111Pages
当調査資料は膵島アミロイドポリペプチドのグローバル市場について調査・分析したレポートです。種類別（AC-253、DACRA-042、DACRA-089、KBP-056、KBP-088、その他）市場規模、用途別（代謝性疾患、胃腸、筋骨格系障害、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、...

家族性大腸腺腫症治療の世界市場（～2026年）

Global Familial Adenomatous Polyposis Treatment Market Insights and Forecast to 2026
MRC2-11QY05958 2020年11月20日 112Pages
当調査資料は家族性大腸腺腫症治療のグローバル市場について調査・分析したレポートです。種類別（イコサペント、塩酸エフロルニチン、アスピリン、CEQ-508、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア...

皮膚糸状菌性爪真菌症治療薬（DOT）の世界市場（～2026年）

Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Size, Status and Forecast 2020-2026
MRC2-11QY11621 2020年11月25日 93Pages
当調査資料は皮膚糸状菌性爪真菌症治療薬（DOT）のグローバル市場について調査・分析したレポートです。種類別（局所、経口療法）市場規模、用途別（病院、皮膚科・足病医院、独立薬局、通信販売薬局、ドラッグストア）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア...

市中肺炎（CAP）の世界市場（～2026年）

Global Community Acquired Pneumonia (CAP) Market Size, Status and Forecast 2020-2026
MRC2-11QY11452 2020年11月25日 92Pages
当調査資料は市中肺炎（CAP）のグローバル市場について調査・分析したレポートです。種類別（胸部X線/X線撮影、喀痰グラム染色/培養、血液培養）市場規模、用途別（病院・クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国...

トランスサイレチンアミロイドーシス（ATTR）の世界市場（～2026年）

Global Transthyretin Amyloidosis (ATTR) Market Size, Status and Forecast 2020-2026
MRC2-11QY04896 2020年11月20日 92Pages
当調査資料はトランスサイレチンアミロイドーシス（ATTR）のグローバル市場について調査・分析したレポートです。種類別（遺伝性ATTR（HATTR）、野生型（WT）ATTR）市場規模、用途別（病院、外来外科センター、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギ...

抗体薬物複合体（ADC）の世界市場（～2026年）

Global Antibody Drug Conjugates (ADCs) Market Size, Status and Forecast 2020-2026
MRC2-11QY10862 2020年11月25日 94Pages
当調査資料は抗体薬物複合体（ADC）のグローバル市場について調査・分析したレポートです。種類別（シアトルジェネティクス技術、イミュノジェン技術、イミュノメディクス技術）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシ...

非アルコール性脂肪性肝炎（NASH）の世界市場（～2026年）

Global Nonalcoholic Steatohepatitis (NASH) Market Size, Status and Forecast 2020-2026
MRC2-11QY03996 2020年11月20日 95Pages
当調査資料は非アルコール性脂肪性肝炎（NASH）のグローバル市場について調査・分析したレポートです。種類別（オベチコール酸（OCA）、セロンセルチブ、エムリカサン、GR-MD-02、IMM-124E）市場規模、用途別（病院薬局、オンラインプロバイダー、小売薬局）市場規模、地域別（北米、米国、カナダ、...

造血幹細胞移植（HSCT）の世界市場（～2026年）

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Size, Status and Forecast 2020-2026
MRC2-11QY12152 2020年11月25日 92Pages
当調査資料は造血幹細胞移植（HSCT）のグローバル市場について調査・分析したレポートです。種類別（同種異系、自家）市場規模、用途別（末梢血幹細胞移植（PBSCT）、骨髄移植（BMT）、臍帯血移植（CBT））市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア...

膵島アミロイドポリペプチドの世界市場（～2026年） Market Analysis and Insights: Global Islet Amyloid Polypeptide Market The global Islet Amyloid Polypeptide market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Islet Amyloid Polypeptide Scope and Market Size Islet Amyloid P…
家族性大腸腺腫症治療の世界市場（～2026年） Market Analysis and Insights: Global Familial Adenomatous Polyposis Treatment Market The global Familial Adenomatous Polyposis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Familial Adenomatous Polyposis Tr…
ヘテロ接合性家族性高コレステロール血症薬の世界市場（～2026年） Market Analysis and Insights: Global Heterozygous Familial Hypercholesterolemia Drug Market The global Heterozygous Familial Hypercholesterolemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Heterozygous Famili…
ホモ接合性家族性高コレステロール血症治療の世界市場（～2026年） Market Analysis and Insights: Global Homozygous Familial Hypercholesterolemia Treatment Market The global Homozygous Familial Hypercholesterolemia Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Homozygous Fa…
トランスサイレチンの世界市場（～2026年） Market Analysis and Insights: Global Transthyretin Market The global Transthyretin market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Transthyretin Scope and Market Size Transthyretin market is segmented by Type, and by A…